To sum up, our study validates the safety and efficacy of CAR‐T cell therapy targeting CD19 in 10 pediatric patients, which encourage us to explore more patients with relapse/refractory B‐ALL in the future. Here, CD19 is linked to acute lymphoblastic leukemia.